Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diosmin for Delayed-onset Muscle Soreness in Female Athletes
NCT06125002Phase 1Unknown
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in delayed onset muscle soreness (DOMS) comparing Placebo with Diosmin (2 arms). Primary endpoint: Muscle soreness at 48 hours. Status: unknown.
02
Drugs
diosmin
03
Conditions
delayed onset muscle soreness (DOMS)
Beyond the preview
Go deeper on NCT06125002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125002.